Explore

USA Today USA Today
Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America's CEO said the company spends more than $250 million a year on GLP-1 drugs for employees, calling the growing cost a worthwhile investment.
Trendline Trendline
Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs

Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs

Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs
Trendline Trendline
Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications

Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications

Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications
Trendline Trendline
Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication

Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication

Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication
Trendline Trendline
Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health
Trendline Trendline
Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees

Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees

Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees
Trendline Trendline
Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market

Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market

Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market
Trendline Trendline
Amazon Expands Healthcare Offerings with Medicare Weight-Loss Drug Program

Amazon Expands Healthcare Offerings with Medicare Weight-Loss Drug Program

Amazon Expands Healthcare Offerings with Medicare Weight-Loss Drug Program
Trendline Trendline
Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health Benefits

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health Benefits

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health Benefits
Trendline Trendline
Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs

Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs

Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs
TheStreet TheStreet
Novo Nordisk CEO resets expectations for Wegovy's explosive growth

Novo Nordisk CEO resets expectations for Wegovy's explosive growth

I believe that when a stock is down nearly 10% year to date and down 38% over three years, the CEO's job on a quarterly earnings call is not just to report results. It is to rebuild a narrative that investors have lost confidence in. And Novo Nordisk CEO Mike Doustdar is honestly trying that with ...
Trendline Trendline
Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports

Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports

Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports